Cart
sales@molnova.com
Orelabrutinib
CAS No. 1655504-04-3
Orelabrutinib( ICP-022 )
Catalog No. M22427 CAS No. 1655504-04-3
Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 177 | In Stock |
|
| 10MG | 299 | In Stock |
|
| 25MG | 492 | In Stock |
|
| 50MG | 682 | In Stock |
|
| 100MG | 896 | In Stock |
|
| 500MG | 1791 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOrelabrutinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionOrelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
-
DescriptionOrelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK). (In Vitro):With a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.(In Vivo):Upon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
-
In VitroWith a proprietary formulation, Orelabrutinib (ICP-022) achieves high bioavailability comparing to other BTK inhibitors.
-
In VivoUpon administration, Orelabrutinib (ICP-022) binds to and inhibits the activity of BTK. This prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK.
-
SynonymsICP-022
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1655504-04-3
-
Formula Weight427.5
-
Molecular FormulaC26H25N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:250 mg/mL (584.80 mM; Need ultrasonic)
-
SMILESNC(=O)c1ccc(nc1-c1ccc(Oc2ccccc2)cc1)C1CCN(CC1)C(=O)C=C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.
molnova catalog
related products
-
MDVN-1003
A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively.
-
NX-2127
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.
-
PRN 1008
PRN1008 is a novel reversible, covalent and oral inhibitor of BTK with biochemical IC50 of 1.3 nM.
